Close Menu

NEW YORK (GenomeWeb) – Dicerna Pharmaceuticals last week reported its third-quarter financial results, posting higher losses amid increased spending on its drug-development programs.

Dicerna's net loss for the period rose to $11.2 million from $4.5 million the year before.

Meanwhile, research and development costs climbed to $7.5 million from $2.4 million, reflecting the initiation of clinical testing of its Phase I cancer drug DCR-MYC and preparations to advance the preclinical primary hyperoxaluria 1 treatment DCR-PH1 into human trials.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

A bill passed by a US House of Representatives appropriations subcommittee would give scientific agencies including the National Science Foundation boosts in funding.

University of Idaho researchers model the scientific discovery process to examine the link between reproducibility and scientific truth.

Relocating USDA agencies outside of Washington, DC, may make them less effective, critics of the move tell NPR.

In PLOS this week: genes that help Borrelia burgdorferi survive in ticks, CiliaCarta collection of about 1,000 suspected cilia genes, and more.

May
21
Sponsored by
Qiagen

This webinar will provide a first-hand look at how a hematology/oncology lab in the UK set up and validated three molecular assays for routine in-house use.

Jun
04
Sponsored by
NanoCellect

This webinar will discuss a study that used CRISPR/Cas9 to engineer mice harboring risk variants associated with glaucoma in order to assess their functional relevance. 

Jun
06
Sponsored by
NRGene & Illumina

This webinar will discuss the impact of affordable de novo genome assemblies on crop research.